The article reports on the incremental survival improvements in advanced colorectal cancer (ACRC) in Canada. It provides a detailed understanding on the cytotoxic therapy and targeted agents for ACRC, including bevacizumab and epidermal growth factor receptor inhibitors (EGFR). It also discusses the recent advances of bevacizumab beyond progression, along with highlights on aflibercept and regorafenib.